Clinical trial
Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
NCT02552147 is registered in ClinicalTrials.gov with Yale University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
- Lead sponsor
- Yale University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2015
- Completion date
- November 17, 2017
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
aggression, autism spectrum disorder, irritability